Modeled dose-response onset geometry for sildenafil is a PK→PD construct describing how absorption rate, absorption timing, solubility, gastric emptying, distribution loading, distribution geometry, clearance geometry, and dose-scaling geometry shape rising-phase trajectories across modeled dose levels. In this framework, onset refers only to a mathematical PK→PD transition coordinate and not to real-world timing. Absorption rate influences modeled rising-phase steepness, while absorption timing determines temporal alignment of the input curve. Solubility contributes to dissolution-driven availability, and gastric emptying affects modeled input arrival. Distribution loading defines early compartment representation, distribution geometry describes movement across modeled spaces, and clearance geometry determines concentration removal characteristics. Dose-scaling geometry defines how 25 mg, 50 mg, and 100 mg inputs are represented within the simulation. PD interpretation then transforms PK trajectories through threshold placement, binding sensitivity, coupling geometry, and PD noise bands to create modeled onset geometry. Link to onset time.
Modeled peak and Tmax geometry across dose-response simulations describes how PK trajectory structures are transformed into peak-related coordinates. Faster modeled absorption produces a steeper rising phase, while earlier absorption timing shifts the input curve position within the model. Solubility influences dissolution-driven availability, and gastric-emptying parameters modify the distribution of modeled input arrival. Distribution loading determines early central-compartment representation, distribution geometry describes compartmental spread, and clearance geometry shapes the descending trajectory. Dose-scaling geometry determines how peak amplitude and curve curvature vary between modeled dose inputs. Concentration-dependent clearance can modify trajectory shape when removal behavior changes across concentration ranges. Under peak and Tmax modeling, PK geometry supplies concentration curves that are transformed by PD parameters into modeled coordinates. These relationships describe simulation structure only and do not indicate real-world peak timing. Link to peak sildenafil.
PD geometry determines how sildenafil dose-response PK trajectories are translated into modeled onset and peak differences. Threshold placement defines where each concentration curve intersects a modeled transition coordinate. Binding sensitivity controls how concentration variation is converted into modeled binding variation; higher modeled sensitivity can expand separation between trajectories, while lower sensitivity can compress differences. Coupling geometry defines how binding relationships are mapped into downstream mathematical signals, with different slopes producing broader or narrower transitions. PD noise bands create interpretation ranges around calculated coordinates. Because dose-response models can use different PK parameter combinations involving absorption rate, solubility, gastric emptying, distribution loading, distribution geometry, Tmax geometry, and Cmax geometry, PD mapping can expand or compress modeled onset and peak differences. These dose-response speed relationships remain strictly within PK→PD interpretation geometry. Link to peak variability comparison.
PK geometry defines the concentration trajectories used for sildenafil dose-response modeling. Absorption rate controls the modeled steepness of the rising phase, while absorption timing determines the temporal location of input appearance. Solubility contributes to dissolution-driven availability, and gastric emptying modifies the modeled arrival profile. Distribution loading represents early concentration placement, while distribution geometry describes movement between modeled compartments. Redistribution timing influences later trajectory transitions. Clearance geometry, first-pass metabolism, and bioavailability affect concentration persistence and removal patterns. Dose-scaling geometry determines how different dose inputs are represented within the model. Tmax geometry identifies the modeled peak location, while Cmax geometry defines the modeled peak amplitude structure. Concentration-dependent clearance can alter trajectory curvature. These parameters collectively generate dose-response PK curves that are later transformed by PD rules. Link to absorption rate.
PK variability creates different modeled onset and peak windows across dose levels by changing the structure of simulated concentration trajectories. Differences in absorption rate, absorption window width, gastric emptying, solubility, distribution loading, redistribution timing, metabolism geometry, elimination geometry, and bioavailability modify the PK curve. Tmax geometry and Cmax geometry change the location and amplitude of trajectory features within the simulation. Dose-scaling geometry determines how each input is mathematically positioned relative to other dose structures. These PK variations are interpreted through PD transformation parameters including thresholds, sensitivity, coupling, and noise bands. The resulting dose-response geometry reflects parameter interactions within a PK→PD framework and does not describe observed timing, clinical outcomes, or individual biological responses. Link to distribution speed.
| PK Domain | Dose-Response Interaction | Link |
|---|---|---|
| Absorption Rate | Steeper or flatter rising phase. | absorption rate |
| Distribution Geometry | Compartmental spread. | distribution speed |
| Clearance | Removal geometry. | elimination speed |
PD interpretation transforms sildenafil dose-response PK curves into modeled onset and peak coordinates. Threshold placement defines the concentration boundary used for assigning a modeled transition location. Binding sensitivity determines how concentration differences are converted into modeled interaction differences. Coupling geometry describes the mathematical relationship between binding variables and downstream signal representation. PD noise bands define ranges around calculated coordinates. These modifiers operate after PK trajectory generation and determine how dose-linked concentration changes are represented within the model. Alterations in threshold position, sensitivity parameters, coupling slopes, and noise ranges can change the shape of modeled dose-response geometry. These effects describe mathematical transformation behavior rather than real-world timing or response patterns. Link to pd speed.
Binding sensitivity, coupling geometry, and PD noise bands influence whether modeled dose-response onset and peak differences appear compressed or expanded. Higher sensitivity values can increase separation between simulated concentration trajectories, while lower values can reduce visible differences. Coupling geometry controls downstream transformation slope and curvature, producing different modeled transition profiles. Noise bands modify the width of interpretation regions surrounding calculated coordinates. Combined with PK parameters such as absorption rate, Tmax geometry, Cmax geometry, distribution geometry, and clearance geometry, these PD modifiers create a complete PK→PD mapping system. The resulting geometry explains parameter interactions within dose-response simulations without extending interpretation into real-world effectiveness or outcomes. Link to pk speed.
| PD Domain | Dose-Response Effect | Link |
|---|---|---|
| Threshold Placement | Earlier/later PD coordinate. | onset time |
| Binding Sensitivity | Amplification/compression. | onset variability comparison |
| Coupling Geometry | Slope-driven shaping. | peak variability comparison |
Modeled dose-response onset and peak differences are determined by interactions between PK trajectory parameters and PD transformation parameters. PK factors include absorption rate, absorption timing, solubility, gastric emptying, absorption window width, distribution loading, distribution geometry, redistribution timing, clearance geometry, first-pass metabolism, bioavailability, dose-scaling geometry, Tmax geometry, Cmax geometry, and concentration-dependent clearance. These variables define the mathematical concentration curves used in the simulation. PD factors including threshold placement, binding sensitivity, coupling geometry, and noise bands then transform those curves into modeled coordinates. Differences between trajectories represent parameter-driven changes within a PK→PD model. They do not represent observed onset timing, peak timing, clinical effectiveness, or individual biological outcomes.
PK mechanisms shaping dose-response onset and peak geometry include processes controlling modeled concentration input, distribution, and removal. Absorption rate influences rising-phase steepness, while absorption timing determines input alignment. Solubility and gastric emptying contribute to the structure of the absorption profile. Distribution loading and distribution geometry define movement across modeled compartments. Redistribution timing affects later trajectory phases. Clearance geometry, first-pass metabolism, and bioavailability modify concentration availability. Dose-scaling geometry determines how different dose inputs are represented mathematically. Tmax and Cmax geometry describe peak-related trajectory features. These mechanisms explain simulation behavior only and do not represent real-world absorption, onset, or peak characteristics.
PD mechanisms shape dose-response interpretation by transforming PK concentration trajectories into modeled coordinates. Threshold placement establishes the concentration boundary used for transition assignment. Binding sensitivity controls the relationship between concentration variation and modeled binding variation. Coupling geometry defines how binding relationships propagate through mathematical signal structures. PD noise bands introduce ranges around calculated coordinates. Together, these parameters determine how differences between dose-linked PK curves appear within the model. PD transformation occurs after PK trajectory creation and modifies interpretation geometry. These mechanisms describe mathematical relationships inside a PK→PD framework and do not represent clinical response measurements, effectiveness assessments, or individual outcomes.
Modeled dose-response trajectories differ because simulations can use different combinations of PK and PD parameters. Changes in absorption rate, absorption timing, solubility, gastric emptying, absorption window width, distribution loading, distribution geometry, redistribution timing, clearance geometry, bioavailability, first-pass metabolism, and dose-scaling assumptions alter concentration curves. Tmax geometry and Cmax geometry may shift as underlying parameters change. PD factors including threshold placement, binding sensitivity, coupling geometry, and noise bands further modify the translated dose-response geometry. These differences represent sensitivity to model inputs and assumptions. They do not indicate observed timing patterns, real-world performance, or individual biological behavior.
PK→PD mapping explains modeled dose-response onset and peak differences by connecting concentration trajectory generation with PD transformation rules. The PK layer creates curves using absorption, distribution, metabolism, elimination, dose-scaling, Tmax, and Cmax parameters. The PD layer applies thresholds, binding sensitivity, coupling relationships, and noise ranges to convert those curves into modeled coordinates. Changes in PK parameters modify the input trajectory, while changes in PD parameters modify interpretation of that trajectory. The resulting dose-response geometry reflects interactions between both model layers. This framework describes simulated parameter relationships only and does not represent measured timing, effectiveness, safety, or individual response characteristics.